-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
ROIV:NSD- (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 10.57Change
-0.26 (-2.40)%Market Cap
USD 8.01BVolume
3.25MVerdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Biotechnology |
Last Closing
USD 10.57Change
-0.26 (-2.40)%Market Cap
USD 8.01BVolume
3.25MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
VRTX | Vertex Pharmaceuticals Inc |
-3.79 (-0.80%) |
USD 122.24B |
REGN | Regeneron Pharmaceuticals Inc |
+0.17 (+0.02%) |
USD 115.08B |
MRNA | Moderna Inc |
-2.43 (-2.01%) |
USD 51.07B |
ALNY | Alnylam Pharmaceuticals Inc |
-4.00 (-1.62%) |
USD 28.20B |
ARGX | argenx NV ADR |
-14.90 (-3.35%) |
USD 26.78B |
BNTX | BioNTech SE |
-0.02 (-0.02%) |
USD 20.40B |
BGNE | BeiGene Ltd |
-2.91 (-2.00%) |
USD 17.50B |
GMAB | Genmab AS |
-0.45 (-1.76%) |
USD 16.65B |
BMRN | Biomarin Pharmaceutical Inc |
-1.17 (-1.40%) |
USD 15.98B |
RPRX | Royalty Pharma Plc |
-0.30 (-1.12%) |
USD 15.90B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
TYNE | 4.21 % | 0.00 % |
N/A |
N/A | |
FHH:CA | First Trust AlphaDEX US H.. | 0.00 % | 0.77 % |
-0.10 (0%) |
CAD 9.67M |
FHH-F:CA | First Trust AlphaDEX U.S... | 0.00 % | 0.00 % |
N/A |
CAD 0.01B |
DSPC | 0.00 % | 0.00 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -5.88% | 60% | D- | 46% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -5.88% | 60% | D- | 45% | F | ||
Trailing 12 Months | |||||||
Capital Gain | 4.97% | 73% | C | 62% | D | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 4.97% | 72% | C | 57% | F | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 41.57% | 84% | B | 89% | A- | ||
Dividend Return | 41.57% | 84% | B | 89% | A- | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 68.59% | 41% | F | 24% | F | ||
Risk Adjusted Return | 60.60% | 97% | N/A | 85% | B | ||
Market Capitalization | 8.01B | 98% | N/A | 92% | A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.